Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Mar 13, 2015 4:23pm

439 Views

Post# 23519478

RE:RE:RE:RVX PRESENTATIONS

It very effectively communicates the effectiveness of RVX-208 in the proper patient population and is a great advertisement for why to be excited for BETonMace. It surely won't have the bang that would have come with meeting the primary endpoints of a Phase II or Phase III trial. However, a huge challenge in the Cardiology field is how to reduce MACE in the diabetic population. RVX-208 , in post-hoc analysis of Phase II trials, seems to do what no other drug on the market can do, which is reduce MACE AND fasting glucose in diabetic patients. So yes, should be much interest IMO

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale